Home Medicine Family experience with individuals of different ages and clinical presentations diagnosed with DI: do familial DI cases tolerate polyuria better?
Article
Licensed
Unlicensed Requires Authentication

Family experience with individuals of different ages and clinical presentations diagnosed with DI: do familial DI cases tolerate polyuria better?

  • Hakan Birinci ORCID logo EMAIL logo , Emrullah Arslan ORCID logo , Tansu Değirmenci and Bumin N. Dündar
Published/Copyright: September 10, 2025

Abstract

Objectives

Familial neurohypophyseal diabetes insipidus (DI) is a rare genetic disorder caused by vasopressin deficiency due to AVP gene mutations. This case report describes the genetic findings and clinical profiles of three generations within a family affected by hereditary central DI and managed with desmopressin.

Case presentation

An 8-month-old male infant was admitted due to persistent polyuria and polydipsia that had been present since birth. History revealed a daily fluid intake of 7,200 mL and required 13 full diapers. The water deprivation test revealed a serum osmolality >300 mOsm/kg with a concurrently low urine osmolality (<300 mOsm/kg), confirming the diagnosis of DI. Desmopressin therapy was initiated for the patient. Using next-generation sequencing, a heterozygous variant c.329G>A (p.Cys110Tyr) was detected in the AVP gene. Following our patient’s diagnosis, we evaluated first cousin once removed (on the maternal side) for similar symptoms. Upon identification of the heterozygous AVP variant via next-generation sequencing, desmopressin treatment was started. The same variant was detected in our patient’s grandfather, mother, aunt, great-uncle, and first cousin once removed. Polyuria and polydipsia were present in all patients included in our case series. The grandfather and great-uncle, who were initially diagnosed, experienced delayed diagnosis and later developed renal complications. In contrast, the following generations of the family were diagnosed early.

Conclusions

In familial cases, parents are often familiar with the clinical features of DI, allowing them to ensure adequate hydration, manage polyuria, and minimize the risk of dehydration. However, early diagnosis reduces the risk of long-term complications and enables effective family screening, allowing identification of previously unrecognized mild cases.


Corresponding author: Dr. Hakan Birinci, Pediatric Endocrinology Clinic, Ministry of Health Izmir City Hospital, Izmir, Türkiye, E-mail:

  1. Research ethics: Not applicable.

  2. Informed consent: Informed consent was obtained from all individuals included in this study, or their legal guardians or wards.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission. Hakan Birinci and Emrullah Arslan contributed to patient evaluation, data collection, and drafting of the manuscript. Hakan Birinci performed the literature review and finalized the manuscript. Tansu Değirmeci and Bumin Nuri Dündar critically revised the manuscript and contributed to the interpretation of clinical data.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: Not applicable.

References

1. Baylis, PH, Robertson, GL. Vasopressin function in familial cranial diabetes insipidus. Postgrad Med J 1981;57:36–40. https://doi.org/10.1136/pgmj.57.663.36.Search in Google Scholar PubMed PubMed Central

2. Arima, H, Morishita, Y, Hagiwara, D, Hayashi, M, Oiso, Y. Endoplasmic reticulum stress in vasopressin neurons of familial diabetes insipidus model mice: aggregate formation and mRNA poly(A) tail shortening. Exp Physiol 2014;99:66–71. https://doi.org/10.1113/expphysiol.2013.072553.Search in Google Scholar PubMed

3. Lee, YW, Lee, KW, Ryu, JW, Mok, JO, Ki, CS, Park, HK, et al.. Mutation of Glu78 of the AVP-NPII gene impairs neurophysin as a carrier protein for arginine vasopressin in a family with neurohypophyseal diabetes insipidus. Ann Clin Lab Sci 2008;38:12–4.Search in Google Scholar

4. Bichet, DG. Genetics and diagnosis of central diabetes insipidus. Ann Endocrinol 2012;73:117–27. https://doi.org/10.1016/j.ando.2012.03.030.Search in Google Scholar PubMed

5. Stenson, PD, Mort, M, Ball, EV, Evans, K, Hayden, M, Heywood, S, et al.. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet 2017;136:665–77. https://doi.org/10.1007/s00439-017-1779-6.Search in Google Scholar PubMed PubMed Central

6. Rutishauser, J, Böni-Schnetzler, M, Böni, J, Wichmann, W, Huisman, T, Vallotton, MB, et al.. A novel point mutation in the translation initiation codon of the pre-pro-vasopressin-neurophysin II gene: cosegregation with morphological abnormalities and clinical symptoms in autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol metabolism 1996;81:192–8. https://doi.org/10.1210/jcem.81.1.8550751.Search in Google Scholar PubMed

7. Rittig, S, Siggaard, C, Ozata, M, Yetkin, I, Gregersen, N, Pedersen, EB, et al.. Autosomal dominant neurohypophyseal diabetes insipidus due to substitution of histidine for tyrosine(2) in the vasopressin moiety of the hormone precursor. J Clin Endocrinol Metab 2002;87:3351–5. https://doi.org/10.1210/jcem.87.7.8677.Search in Google Scholar PubMed

8. Christensen, JH, Siggaard, C, Rittig, S. Autosomal dominant familial neurohypophyseal diabetes insipidus. APMIS Suppl 2003;111:92–5.Search in Google Scholar

9. Davies, J, Murphy, D. Autophagy in hypothalamic neurones of rats expressing a familial neurohypophysial diabetes insipidus transgene. J Neuroendocrinol 2002;14:629–37. https://doi.org/10.1046/j.1365-2826.2002.00822.x.Search in Google Scholar PubMed

10. Willcutts, MD, Felner, E, White, PC. Autosomal recessive familial neurohypophyseal diabetes insipidus with continued secretion of mutant weakly active vasopressin. Hum Mol Genet 1999;8:1303–7. https://doi.org/10.1093/hmg/8.7.1303.Search in Google Scholar PubMed

11. Davies, JH, Penney, M, Abbes, AP, Engel, H, Gregory, JW. Clinical features, diagnosis and molecular studies of familial central diabetes insipidus. Hormone Res 2005;64:231–7. https://doi.org/10.1159/000089291.Search in Google Scholar PubMed

12. Sasaki, Y, Higashihara, E, Takeuchi, T, Nutahara, K, Homma, Y, Aso, Y. A case of familial central diabetes insipidus: the response of urinary prostaglandins to 1-deamino-8-D-arginine vasopressin. J urology 1994;152:161–3. https://doi.org/10.1016/s0022-5347(17)32845-8.Search in Google Scholar PubMed

13. Tian, D, Cen, J, Nie, M, Gu, F. Identification of five novel arginine vasopressin gene mutations in patients with familial neurohypophyseal diabetes insipidus. Int J Mol Med 2016;38:1243–9. https://doi.org/10.3892/ijmm.2016.2703.Search in Google Scholar PubMed

14. Mahoney, CP, Weinberger, E, Bryant, C, Ito, M, Jameson, JL, Ito, M. Effects of aging on vasopressin production in a kindred with autosomal dominant neurohypophyseal diabetes insipidus due to the ΔE47 neurophysin mutation. J Clin Endocrinol Metab 2002;87:870–6. https://doi.org/10.1210/jcem.87.2.8270.Search in Google Scholar PubMed

15. Braverman, LE, Mancini, JP, McGoldrick, DM. Hereditary idiopathic diabetes insipidus. A case report with autopsy findings. Ann Intern Med 1965;63:503–8. https://doi.org/10.7326/0003-4819-63-3-503.Search in Google Scholar PubMed

16. Brachet, C, Birk, J, Christophe, C, Tenoutasse, S, Velkeniers, B, Heinrichs, C, et al.. Growth retardation in untreated autosomal dominant familial neurohypophyseal diabetes insipidus caused by one recurring and two novel mutations in the vasopressin-neurophysin II gene. Eur J Endocrinol 2011;164:179–87. https://doi.org/10.1530/eje-10-0823.Search in Google Scholar

17. Gu, F, Jin, Z, Zhang, D. The etiology and clinical characteristics of central diabetes insipidus, a retrospective study of 408 cases. Zhonghua Yi Xue Za Zhi 2001;81:1166–71.Search in Google Scholar

18. Spiess, M, Beuret, N, Rutishauser, J. Genetic forms of neurohypophyseal diabetes insipidus. Best Pract Res Clin Endocrinol Metab 2020;34:101432. https://doi.org/10.1016/j.beem.2020.101432.Search in Google Scholar PubMed

19. Russell, TA, Ito, M, Ito, M, Yu, RN, Martinson, FA, Weiss, J, et al.. A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons. J Clin Invest 2003;112:1697–706. https://doi.org/10.1172/jci200318616.Search in Google Scholar

20. Nguyen, HT, Alkhidir, A, Lagos, YV, Le, PTV, Nguyen, LH. Challenges in diagnosing and managing severe hypernatremia in patients with major depressive disorder: a case report. Cureus 2024;16:e64281. https://doi.org/10.7759/cureus.64281.Search in Google Scholar PubMed PubMed Central

21. Habiby, R, Bichet, DG, Arthus, MF, Connaughton, D, Shril, S, Mane, S, et al.. A novel form of familial vasopressin deficient diabetes insipidus transmitted in an X-linked recessive manner. J Clin Endocrinol Metab 2022;107:e2513–2. https://doi.org/10.1210/clinem/dgac076.Search in Google Scholar PubMed PubMed Central

Received: 2025-06-17
Accepted: 2025-08-25
Published Online: 2025-09-10
Published in Print: 2025-12-17

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Review
  3. Subclinical but significant? Updated review of pediatric hypothyroidism
  4. Original Articles
  5. The differential impact of automated insulin delivery systems on body mass index in children with type 1 diabetes
  6. Maturity-onset diabetes of the young due to HNF1β variants (HNF1β-MODY): a 2-year follow-up study of six patients from a single diabetes center
  7. Investigating the kynurenine pathway in pediatric metabolic health
  8. Mucolipidosis type II and III: clinical spectrum, genetic landscape, and longitudinal outcomes in a pediatric cohort with six novel mutations
  9. Evaluation of the genetic alterations landscape of differentiated thyroid cancer in children
  10. Prognostic analysis of persistent disease in medium-to high-risk children and adolescents with differentiated thyroid carcinoma
  11. The clinical picture of symptomatic Rathke cleft cysts in children
  12. Pitfalls in the diagnosis of carnitine palmitoyltransferase 1 deficiency
  13. Effective treatment of hyperphosphatemia with denosumab in patients with loss of function of FGF23 and high bone density: case series
  14. Case Reports
  15. Dual molecular genetic diagnosis with combined malonic and methylmalonic aciduria (CMAMMA): implications of coexisting genetic disorders on clinical presentation
  16. Family experience with individuals of different ages and clinical presentations diagnosed with DI: do familial DI cases tolerate polyuria better?
  17. Atypical pediatric presentation of hyperparathyroidism: CDC73 gene mutation and parathyroid carcinoma
  18. Pseudohypertriglyceridemia as a clue: clinical and genetic spectrum of glycerol kinase deficiency in three pediatric cases
  19. Transient worsening of thyrotoxic myopathy following methimazole and metoprolol initiation in a 12-year-old girl: a case report and literature review
  20. Letter to the Editor
  21. Cognitive behavioral therapy (CBT) effect on diabetic youth depression, death anxiety and glycemic control
  22. Annual Reviewer Acknowledgment
  23. Reviewer Acknowledgment
Downloaded on 9.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2025-0342/html
Scroll to top button